Theralink

BEYOND GENOMICS

BEYOND GENOMICS

Protein drug target activation mapping to change the paradigm in precision medicine based cancer therapy

Presentation by
Avant Diagnostics on Theralink’s Reverse
Phase Protein Array (RPPA) Technology.

ENABLING PHYSICIANS TO MAKE PERSONALIZED TREATMENT RECOMMENDATIONS FOR CANCER PATIENTS

ENABLING PHYSICIANS TO MAKE PERSONALIZED TREATMENT RECOMMENDATIONS FOR CANCER PATIENTS

Theralink may enable clear decision making for an individual patient’s cancer treatment using protein biomarkers.

EARLY AND LATE STAGE DRUG DEVELOPMENT

EARLY AND LATE STAGE DRUG DEVELOPMENT

FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES

Theralink biopharma services will help drug companies accelerate their drug discovery programs.

Preclinical

Evaluate the on-target and off-target effects of your drug in our laboratory with the latest technologies

Companion Diagnostic

Partner with Theralink Technologies to maximize the potential of your therapeutics

Clinical

Utilize our technology to stratify patients as potential responders/non responders in your clinical trials

Ask a Proteomic Scientist

Talk to one of our team members on how Theralink Technologies can assist you

WE’LL ENSURE YOU ALWAYS RECEIVE
OPTIMAL DATA.

WE’LL ENSURE YOU ALWAYS RECEIVE
OPTIMAL DATA.

600

Protein targets

Our RPPA technology can evaluate over 600 different protein and phosphoprotein targets

1000+

Peer-reviewed publications

Our company builds upon 1000+ peer-reviewed publications using the RPPA technology to advance precision medicine

7

Scientific patents

Our services are supported by seven patents covering the RPPA technology and the phosphoproteome

WHAT PEOPLE SAY ABOUT OUR TESTS

WHAT PEOPLE SAY ABOUT OUR TESTS

INVEST IN THERALINK: THE FUTURE OF PRECISION MEDICINE

INVEST IN THERALINK: THE FUTURE OF PRECISION MEDICINE

REQUEST MORE INFORMATION